In the group with an age at breast cancer diagnosis of <50 years, it was observed that the 5-year cumulative probability of osteoporosis was higher in women who received AIs monotherapy at 34.7% than in those who received AIs following a combination of chemotherapy and anti-HER2 therapy at 31.8%. This evidence concerns the gene ERBB2 and breast carcinoma.